NRX Pharmaceuticals, Inc. Cash Flow Statement
NRXP|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$11M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
NRX Pharmaceuticals, Inc. used $11M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$25.1M | -$30.1M |
| Depreciation & Amortization | $5.0K | $5.0K |
| Operating Cash Flow | -$10.6M | -$21.7M |
| Capital Expenditures | - | $3.0K |
| Free Cash Flow | - | -$21.7M |